# Versterken van eigen emotionele veerkracht tijdens behandeling met antidepressiva.

No registrations found.

**Ethical review** Positive opinion **Status** Recruiting

Health condition type -

**Study type** Interventional

# **Summary**

#### ID

NL-OMON25509

**Source** 

Nationaal Trial Register

**Brief title** REMOD-ID

**Health condition** 

depression (depressie)

## **Sponsors and support**

Primary sponsor: J.J. Van Os, head of department Psychiatry & Neuropsychology,

University of Maastricht

Source(s) of monetary or material Support: Zon-Mw

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

Main outcomes are pre-post intervention change in:

- 1. Depressive symptomatology;
- 2. Daily life emotional experience (in terms on NA and PA) and person-context interaction;
- 3. Pre-post intervention change on the empowerment questionnaire;
- 4. Health care comsumption and costs. In addition, long-term outcome will be examined.

#### **Secondary outcome**

- 1. Change in daily life emotional dynamics during the intervention period will be examined in association with future course of depressive symptomatology;
- 2. Can individual differences in both the effect of feedback on daily life person-context interaction and the predictive value of these daily life emotional dynamics be traced back to genetic variation in polymorphisms related to the brain reward system.

# **Study description**

#### **Background summary**

#### Rationale:

Recent evidence indicates that individual daily life person-context interactions determine vulnerability for depression, and predict relapse as well as recovery. We hypothesize that momentary assessment technology (with the Psy-mate) to monitor these daily life person-context interactions during treatment will enrich passive antidepressant pharmacotherapy with an active resource-mobilising psychotherapeutic context, thus enhancing therapeutic efficacy (reducing symptoms and relapse rate).

#### Objective:

(1) Does feedback on continuous monitoring with the Psy-mate during pharmacotherapy result in a better treatment response (immediate and follow-up reductions of depressive symptoms, decreased relapse risk)? (2) Do measurements of daily life person-context interactions improve the prediction of future courses of depressive symptoms? (3) Can individual differences in (1) the effect of feedback on daily life person-context interaction and (2) the predictive

value of these person-context interactions be traced back to genetic differences?

#### Study design:

Randomized clinical trial with three groups

of 40 subjects each (2 experimental groups and 1 control group). The first group receives a 5-day pre- and post Psy-mate assessment and a continuous Psy-mate assessment (3 days of Psy-mate measurements during a 6-weeks period) with weekly feedback (to both patient and therapist) during treatment as usual (TAU). The second group also receives a 5-day pre- and post Psy-mate assessment and a continuous Psy-mate assessment (3 days of Psy-mate measurements during a 6-weeks period) but without feedback during treatment as usual (TAU). The third group receives a 5-day pre- and post Psy-mate assessment but no additional intervention during TAU. This is the control group.

#### Study population:

A sample of

patients (n=120) with a depressive disorder will be recruited within (i) SEARCH, the research network of mental health institutions within Limburg and South-Brabant, The Netherlands, (ii) general practices and (iii) the general population.

#### Intervention (if applicable):

The Psy-mate

is a recently developed wearable interactive palmtop suitable for the Experienced Sampling Method (ESM) to study subjects in their daily life. The intervention group receives feedback on Psy-mate measurements of the experience of positive emotions in daily life.

#### Main study

parameters/endpoints:

The rate of change in reward experience measured with the Psy-mate, and the change in depression symptomatology measured with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Hamilton Depression Rating Scale (HDRS).

#### Study objective

1. Individualized feedback on the experience of positive emotions in daily life situations (activities, events and social interactions) increases the ability of patients to generate positive emotions. In addition, we hypothesize therefore that the feedback condition combined with antidepressant treatment compared to antidepressant treatment alone is more effective in reducing immediate and follow-up depressive symptomatology and future relapse;

- 2. Giving individualized feedback on relevant daily life person-context interactions during pharmacotherapy is cost-effective compared to treatment as usual;
- 3. Measurement of relevant dynamic daily life behaviours significantly contributes to the prediction of the future course of depressive symptomatology;
- 4. Individual differences in (i) the effect of feedback on daily life person-context interactions and (ii) the predictive value of these person-context interactions can be traced back to genetic differences;
- 5. Subjects who receive feedback on their experience of positieve emotions in daily life will develop an increase in feelings of empowerment compared to subjects who do not receive feedback.

#### Study design

#### Screening:

Hamilton Depression Rating Scale (HAM-17), Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), personality inventory (NEO-PI), Interview for depression symptomatology (IDS), trauma (Childhood Trauma Questionnaire and Recent life Event Scale), PRODISQ, TiC-P, Euroquol-5D and a saliva sample.

#### Baseline:

5 days of measurement with the Psy-mate, and after completion of this period: the depression part of the SCID-I, the HAM-17, and the IDS.

Intervention period (week 2 to 8):

- 1. Intervention group: 3 days/week during a 6 week period of Psy-mate measurements combined with weekly feedback during treatment as usual (TAU);
- 2. Control group 1: 3 days/week during a 6 week period of Psy-mate measurements without weekly feedback during TAU;
- 3. Control group 2: no Psy-mate measurements, no feedback during TAU.

At the end of the intervention period, all 3 groups have to complete the depression part of the SCID-I, the HAM-17, the IDS, and the Empowerment questionnaire.

Post intervention measurement:

5 days of measurement with the Psy-mate, and after completion of this period: the depression part of the SCID-I, the HAM-17, and the IDS.

#### Follow-up measurements:

- 1. 4 weeks after the intervention period: the depression part of the SCID-I, the HAM-17, and the IDS:
- 2. 8 weeks after the intervention period: the depression part of the SCID-I, the HAM-17, and the IDS;
- 3. 12 weeks after the intervention period: the depression part of the SCID-I, the HAM-17, the IDS, TiC-P, PRODISQ, EQ-5D;
- 4. 24 weeks after the intervention period: the depression part of the SCID-I, the HAM-17, the IDS, TiC-P, PRODISQ, EQ-5D, Interview for Recent Life Events.

#### Intervention

The Psy-mate is a recently developed wearable interactive palmtop suitable for the Experience Sampling Method (ESM) to study subjects in their daily life. The intervention group receives feedback on Psy-mate measurements of positive affect in their daily life.

## **Contacts**

#### **Public**

Universiteit Maastricht Capaciteitsgroep Psychiatrie en Neuropsychologie, UM/FHML Locatie Vijverdal, SN-gebouw Postbus 616

Marieke Wichers
Maastricht 6200 MD
The Netherlands
+31-43 - 36 88 669

#### Scientific

Universiteit Maastricht Capaciteitsgroep Psychiatrie en Neuropsychologie, UM/FHML Locatie Vijverdal, SN-gebouw Postbus 616 Marieke Wichers
Maastricht 6200 MD
The Netherlands
+31-43 - 36 88 669

# **Eligibility criteria**

#### Inclusion criteria

- 1. 18-65 years;
- 2. DSM IV diagnosis of current major depressive disorder or a past DSM-IV diagnosis of major depression with residual symptoms (HAM-17>7);
- 3. Use of antidepressants or moodstabilizers;
- 4. Adequate vision;
- 5. Sufficient Dutch language skills.

#### **Exclusion criteria**

No (hypo) manic or mixed episode within the past month.

# Study design

## **Design**

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 01-01-2010

Enrollment: 120

Type: Anticipated

### **IPD** sharing statement

Plan to share IPD: Undecided

## **Ethics review**

Positive opinion

Date: 31-08-2009

Application type: First submission

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL1862 NTR-old NTR1974

Other METC Unimaas: M09-1935

ISRCTN wordt niet meer aangevraagd.

# **Study results**

<b>Summary results</b> N/A		